BEDFORD, Mass.–(BUSINESS WIRE)– Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced preliminary...
VANCOUVER, Washington, March 04, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications,...
DUBLIN, March 4, 2020 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced the publication of results from the phase 3 ENLIGHTEN-1 clinical trial of ALKS 3831 (olanzapine/samidorphan) in the peer-reviewed publication, Journal of Clinical Psychiatry....
AGN-151587 (EDIT-101) is the first in vivo CRISPR medicine to be administered to patients Additional patient enrollment to the BRILLIANCE Clinical Trial is ongoing DUBLIN, Ireland and CAMBRIDGE, Mass., March 04, 2020 (GLOBE NEWSWIRE) — Allergan plc (NYSE: AGN),...
Brighton, United Kingdom – 3 March 2020 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial resistance (AMR), provides a...
Study to enroll a minimum of 65 patients across the United States to evaluate safety and effectiveness of treatment of acute, non-burn skin injuries VALENCIA, Calif. & MELBOURNE, Australia–(BUSINESS WIRE)– AVITA Medical Limited (ASX: AVH,...
Email
Text